Skip to main content
. 2021 Aug 27;13(17):4336. doi: 10.3390/cancers13174336

Figure 3.

Figure 3

Kaplan–Meier estimate for (A) Progression free survival on lenvatinib, defined as time from first dose until objective disease progression; (B) Overall survival from initiation of lenvatinib, defined as time from first dose to death from any cause; dashes indicate censored events.